Biochemical liver function tests parameters do not indicate any difference in the degree of hepatotoxicity in patients with metastatic colorectal carcinoma treated with conventional anticancer drugs regardless the use of bevacizumab
Abstract
Background/Aim. Colorectal carcinoma (CRC) is one the most frequent malignant disease with early liver metastasis. It requires the timely use of anticancer drugs. Current treatment of metastatic CRC consists of conventional anticancer drugs use, but they cause liver damage which is manifested by disorder in biochemical liver function parameters. The addition of one of monoclonal antibodies, e.g. bevacizumab improves their therapeutic effect, but its influence on caused biochemical disturbances is not completely known. Therefore the aim of this study was to compare the level of liver function test parameters in patients treated with conventional anticancer drugs with parameters in patients additionally treated with bevacizumab. Methods. The study was performed on the two groups of adult patients with liver metastatic CRC assigned according to the treatment protocol. One group of the patients (n = 44) was treated with FOLFOX4 (the group 1), and the other one (n = 52) with bevacizumab added to FOLFOX4 treatment protocol (the group 2). Depending on the response of patients, the duration of treatment varied from 2 to 6 months. Standard liver function tests were performed before and after the completion of the treatment. Results. Initial values of some biochemical function test parameters [alkaline phosphatase (ALP) in the group 1 of patients, gamma-glutamyl transferase (GGT) and lactate dehydrogenase (LDH) in both groups] were increased in relation to the normal reference values, with some intergroup differences (p = 0.001). Biochemical disturbances of liver function tests in the group of patients treated with conventional anticancer drugs were due to not only their metastases but also due to the hepatotoxic effect of drugs used. After the treatment, significant differences in biochemical liver tests parameters were found in aspartate aminotransferase (AST), alanine aminotransferase (ALP), GGT and LDH, being lower in the group 2 (patients additionally treated by bevacizumab) (p values were: 0.002 for AST; 0.001 for ALP and GGT; 0.000 for LDH). The levels of the other studied parameters, alanine aminotransferase (ALT) bilirubin, and proteins did not differ significantly between groups both pre- or post-treatment. Conclusion. Both, metastatic CRC and treatment with the conventional anticancer drugs induce significant disturbances of several liver function parameters. The addition of bevacizumab to the conventional anticancer drugs did not affect these disturbances.
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:
http://globocan.iarc.fr, accessed on day/month/year.
Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer 2006; 94(7): 982−99.
Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver me-tastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005; 5 Spec No A: S149−56.
Chibaudel B, Tournigand C, André T, Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012; 4(2): 75−89.
Chun YS, Laurent A, Maru D, Vauthey J. Management of che-motherapy-associated hepatotoxicity in colorectal liver metas-tases. Lancet Oncol 2009; 10(3): 278−86.
King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncolo-gist 2001; 6(2): 162−76.
Field KM, Dow C, Michael M. Part I: Liver function in oncology: Biochemistry and beyond. Lancet Oncol 2008; 9(11): 1092−101.
Field KM, Michael M. Part II: Liver function in oncology: To-wards safer chemotherapy use. Lancet Oncol 2008; 9(12): 1181−90.
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26(33): 5326−34.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335−42.
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal can-cer: A randomized phase III study. J Clin Oncol 2008; 26(12): 2013−9.
Diaz-Rubio E, Gόmez-España A, Massutĩ B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab fol-lowed by XELOX plus bevacizumab or single-agent bevaci-zumab as maintenance therapy in patients with metastatic co-lorectal cancer: The Phase III MACRO TTD Study. Oncolo-gist 2012; 17(1): 15−25.
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluoroura-cil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23(15): 3502−8.
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16): 3706−12.
Hedrick E, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, et al. . Safety of bevacizumab plus chemotherapy as first line treatment of patients with metastatic colorectal cancer: Up-dated results from a large observational registry in the United States (BriTE). J Clin Oncol 2006; 24(18 Suppl): 3536.
Popov I, Tarabar D, Jovanović D, Kovčin V, Micev M, Petrović Z, et al. Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer. Arch Oncol 2007; 15(1−2): 10−4.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer v2. [cited 2012 Feb 11]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf
Singh-Majkić N. Clinical enzymology. Beograd: AID Praktikum; 1993. (Serbian)
Gür T, Demir H, Kotan CM. Tumor markers and biochemical parameters in colon cancer patients before and after chemo-therapy. Asian Pacific J Cancer Prev 2011; 12(11): 3147−50.
Browning JD, Horton JD. Molecular mediators of hepatic steato-sis and liver injury. J Clin Invest 2004; 114(2): 147−52.
Ortega AL, Mena S, Estrela JM. Oxidative and nitrosative stress in the metastatic microenvironment. Cancers (Basel) 2010; 2(2): 274−304.
Lim K, Ancrile BB, Kashatus DF, Counter CM. Tumour mainten-ance is mediated by eNOS. Nature 2008; 452(7187): 646−9.
Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7(2): 97−110.
Sturgeon CM, Duffy M, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry Labora-tory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Can-cers. Clin Chem 2008; 54(12): e11−79.